Stem cell therapy for joint pain and osteoarthritis: what the research actually shows in 2026

What the randomized trials tell us

Stem-cell treatment for knee osteoarthritis has more clinical research behind it than most people realise. A 2025 systematic review and meta-analysis in Stem Cell Research & Therapy evaluated eight randomized controlled trials involving 502 patients with knee osteoarthritis who received mesenchymal stromal cell treatment without additional biologic therapies.

The researchers found significant improvement in pain and function at six months, still present at twelve. WOMAC, VAS pain scores, and KOOS scores all improved compared with control groups. Adverse events were not significantly different from controls.

Other systematic reviews and randomized trials reach broadly similar conclusions: mesenchymal stromal cell therapy can improve pain and function in some patients, although results vary considerably by cell source, dose, patient population, disease severity, and protocol.

So the question in 2026 is no longer whether stem cells do anything for knee osteoarthritis. The evidence says they can. The more useful question is which patients, which cells, which dose, and which method.

Not all stem cell treatments are the same

This is probably the most important thing to understand before you compare clinics. Stem cell therapy is not one standardised treatment. Clinics differ in cell source, concentration, preparation method, delivery technique, and protocol.

Some treatments are essentially cells suspended in fluid and injected into the joint. Others combine cellular therapy with additional biologic or structural materials intended to support tissue repair. That distinction matters enormously once you are talking about advanced cartilage loss.

Cells do not work in isolation inside the body. Tissue regeneration depends on signalling molecules, extracellular matrix, mechanical environment, blood supply, inflammation, and the physical architecture around the cells. Modern tissue engineering is increasingly focused on creating that environment rather than simply delivering cells.

Researchers are studying combinations of stem or stromal cells with biologic matrices, scaffolding systems, extracellular materials, and growth factors, all designed to give cells a structure in which repair can happen. The field is moving quickly.

What about bone-on-bone, Stage 4 osteoarthritis?

Kellgren-Lawrence Grade 4 osteoarthritis is severe disease: extensive cartilage loss, narrowed or eliminated joint space, bone changes, osteophytes, inflammation, pain, and mechanical dysfunction.

Historically these patients were considered poor candidates for regenerative treatment, on the reasoning that there was very little cartilage left to work with. If we are talking about a simple stem-cell injection on its own, there is good reason for that caution. The strongest randomized-trial evidence has involved mild to moderate disease, not completely destroyed joints.

But treating all Grade 4 disease as automatically untreatable is becoming outdated. Research into cell-supported scaffolds and regenerative matrices matters here precisely because cartilage has very little natural ability to heal once its structure is lost. Rather than asking cells to repair a severely damaged surface alone, these approaches try to provide a framework that can support repair.

Some of the clinics we coordinate with use protocols that combine cells with additional biologic and structural components, chosen by the physician for the individual patient. Parts of those protocols are proprietary to the clinic, so the full formulation is not something published online. What can be said is that the intent is different from injecting cells into an arthritic knee and hoping.

None of that means every bone-on-bone knee can be regenerated. It means Grade 4 is no longer an automatic no across the whole field, and that a knee is worth looking at before anyone decides.

Nobody should promise cartilage regeneration

Regenerative medicine is not magic, and no ethical clinic tells every patient that stem cells will grow a new knee.

Some joints are too mechanically damaged for regenerative treatment to reasonably overcome the problem. Severe deformity, major instability, substantial malalignment, or extensive bone destruction can all make joint replacement the more appropriate treatment.

Some patients experience meaningful pain reduction without structural cartilage regeneration. Some see improvements in mobility and function. Some show imaging changes consistent with tissue repair. Biology varies from person to person, which is why a cure is never something to guarantee.

A physician’s job at the consultation is to work out whether there is a reasonable biological and mechanical opportunity here at all, before recommending anything. Ours is to make that consultation easy to get to, and to tell you plainly when the answer is no.

Cell count is only part of the equation

One of the biggest mistakes in this field is focusing on the number of cells injected. Dose matters, but it is one component among many.

This is why two clinics can both advertise stem cell therapy while offering treatments that are biologically very different. What may determine the result includes:

• The remaining cartilage and joint architecture
• The degree of inflammation
• Mechanical alignment of the knee
• Cell type and cell quality
• Cell concentration
• Growth-factor signalling
• The extracellular environment surrounding the cells
• Supportive biologic materials
• Structural scaffolding or matrix support
• Rehabilitation and mechanical loading afterwards

What the current research actually shows

The evidence is encouraging, and it deserves to be described accurately.

A 2025 meta-analysis of eight randomized trials involving 502 patients found statistically significant improvement in pain and function at both six and twelve months after mesenchymal stromal cell treatment.

A separate 2025 systematic review of Level I randomized controlled trials also found evidence supporting improved clinical outcomes with stromal-cell-based therapies, while noting considerable differences between protocols.

Another systematic review, covering 25 randomized controlled trials and more than a thousand participants, found reductions in pain following advanced mesenchymal stromal cell therapy while emphasising that the certainty of some of the evidence remains limited.

That is the honest position: there is genuine clinical evidence, and there are unanswered questions. Both are true at once.

Tissue engineering may be the next step

The most interesting part of the field may not be stem cells alone. It may be cells combined with tissue-engineering technology.

Cartilage is a highly organised tissue. Placing cells into an arthritic joint does not recreate that architecture by itself, which is why researchers are studying biologic scaffolds, matrices, and cell-supporting materials that can help organise repair.

The concept is simple enough. If cells are the biological workers, severely damaged cartilage may also need a structure in which those workers can operate.

These strategies are still under study, and long-term randomized data for advanced osteoarthritis remains limited. But they open possibilities that did not exist when the first generation of stem-cell injections arrived.

Who may be a candidate?

Candidacy is not decided by the words arthritis or bone-on-bone. A proper evaluation by the treating physician may include:

• X-rays and MRI
• Osteoarthritis grade
• Location and extent of cartilage loss
• Joint alignment
• Ligament stability
• Meniscal integrity
• Previous surgeries
• Age
• Metabolic and inflammatory health
• Activity level
• What you are hoping treatment will do

Can regenerative therapy replace knee replacement?

Often the more useful question is whether it can delay one.

Joint replacement is an excellent operation when it is needed, but it is still major surgery. For someone otherwise headed for replacement, several years of improved function and reduced pain can matter a great deal.

For younger patients it matters more, because artificial joints have a finite lifespan and revision surgery is considerably more complicated than the original procedure.

Some patients will still need replacement. Others may postpone it substantially. As the technology improves, the group who may benefit could keep widening.

Seven questions to ask any regenerative medicine clinic

Before agreeing to treatment anywhere, in any country, ask these. The answers tell you more than any brochure.

• What exactly are you treating? Cartilage loss, inflammation, instability, meniscal disease, malalignment, or a combination.
• What type of regenerative treatment are you recommending? “Stem cells” is not a complete answer.
• Why do you believe I am a candidate? It should rest on imaging, symptoms, and joint mechanics.
• What outcome are you realistically expecting? Pain reduction, mobility, cartilage repair, and delaying surgery are different goals.
• How do you measure outcomes? Clinical scoring, imaging, and follow-up matter more than testimonial videos.
• What happens if I do not respond? A legitimate clinic has a follow-up plan.
• What results can you guarantee? The correct answer is none.

The bottom line

Stem-cell therapy for knee osteoarthritis is no longer a fringe idea supported only by testimonials. Randomized controlled trials and systematic reviews now show meaningful improvement in pain and function in appropriately selected patients. At the same time the science is still developing, particularly for severe and bone-on-bone disease.

The old model was simple: once the cartilage was gone, regenerative treatment had nothing to work with. The newer model is more careful. Researchers are investigating ways to combine cells with biologic materials, matrices, and scaffolds designed to create an environment where damaged cartilage may have a better opportunity to repair.

That does not make Stage 4 osteoarthritis easy to treat. It does not mean anyone can promise you a new knee. And it certainly does not make knee replacement obsolete.

What it means is that the answer is no longer automatically that regenerative medicine has nothing to offer you. The question worth asking is not whether stem cells cure bone-on-bone arthritis. It is whether, given the condition of this particular knee and the technologies now available, there is a reasonable opportunity to improve it before replacing it. That is the conversation worth having in 2026.